Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5670894 | 0.84 | CYP3A4 (0.56) | ALDH1A1KDM4E | |
| SCHEMBL11210850 | 0.84 | KMT2A (0.57) | KMT2AHDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL18415454 | 0.83 | METAP2 (0.49) | KMT2AMETAP2ALDH1A1MAPTPOLB | |
| SCHEMBL23808921 | 0.82 | KMT2A (0.47) | KMT2AHDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL885310 | 0.81 | SRC (0.56) | ALDH1A1POLBRAB9A | |
| SCHEMBL30006359 | 0.81 | SRC (0.56) | ALDH1A1POLBRAB9A | |
| SCHEMBL3563691 | 0.81 | METAP2 (0.47) | KMT2AMETAP2ALDH1A1POLBRAB9A | |
| SCHEMBL23417936 | 0.80 | KMT2A (0.46) | KMT2AHDAC1HDAC6ALDH1A1MAPT | |
| SCHEMBL22972298 | 0.80 | NAMPT (0.49) | KMT2AHDAC1 | |
| SCHEMBL23385216 | 0.79 | CYP2C9 (0.50) | METAP2POLBRIPK1AURKAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | claimed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | claimed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | claimed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | claimed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3326715-A1 | OXALIC ACID MONOAMIDE LIGAND, AND USES THEREOF IN COUPLING REACTION OF COPPER-CATALYZED ARYL HALOGEN SUBSTITUTE | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2018-05-30 | — | — | EP | disclosed |
| US-9656962-B2 | Ring-contracted morphinans and the use thereof | PURDUE PHARMA L.P. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2016-11-24 | — | — | US | disclosed |
| US-8497380-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2013-07-30 | — | — | US | disclosed |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | FELDING JAKOB (DK) | 2013-01-10 | — | — | US | disclosed |
| US-8324394-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-12-04 | — | — | US | disclosed |
| US-8148537-B2 | Substituted acetophenones useful as PDE4 inhibitors | LEO PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| EP-2125736-B1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA AS (DK) | 2011-03-30 | — | — | EP | disclosed |
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA (DK) | 2010-02-11 | — | — | US | disclosed |
| EP-2125736-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | Leo Pharma A/S (DK) | 2009-12-02 | — | — | EP | disclosed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| WO-2008077404-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | LEO PHARMA A/S (DK) | 2008-07-03 | — | — | WO | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035908-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3B | KMT2A 3607/4885METAP2 3822/4885HDAC1 368/4885 |
| US-20160340316-A1 | RING-CONTRACTED MORPHINANS AND THE USE THEREOF | OPRM1, OPRL1, OPRK1 | KMT2A 2784/4885METAP2 3937/4885HDAC1 1424/4885 |
| US-20130012716-A1 | SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS | PDE4A, PDE3B, PDE5A | KMT2A 3570/4885METAP2 3694/4885HDAC1 374/4885 |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | ITGA2B, ITGA2, ITGB2 | KMT2A 3126/4885METAP2 1275/4885HDAC1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.